For the current week, the overall ratings of three Pharmaceutical stocks are worse, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This week, VIVUS Inc. (NASDAQ:VVUS) falls to a D (“sell”), worse than last week’s grade of C (“hold”). VIVUS is a biopharmaceutical company engaged in the development and commercialization of therapeutic products for large underserved markets. VVUS also rates an F in Portfolio Grader’s specific subcategory of Equity. As of May 3, 2013, 26.2% of outstanding VIVUS Inc. shares were held short. To get an in-depth look at VVUS, get Portfolio Grader’s complete analysis of VVUS stock.

The rating of Cempra Holdings LLC (NASDAQ:CEMP) declines this week from a C to a D. Cempra manufactures and markets pharmaceutical products. It is a clinical-stage pharmaceutical company, which focuses on developing antibiotics to meet critical unmet medical needs in the treatment of bacterial infectious diseases. The stock gets F’s in Equity and Cash Flow.

For a full analysis of CEMP stock, visit Portfolio Grader.

Corcept Therapeutics (NASDAQ:CORT) ratings are on the decline this week as the company earns an F (“strong sell”). Last week, it received a D (“sell”). Corcept Therapeutics engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders. The stock gets F’s in Equity and Cash Flow. The stock price has fallen 6.1% over the past month, worse than the 3.6% increase the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of CORT stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.